Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880797 · ClinicalTrials.gov registry record
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
A clinical trial of Human Papilloma Virus and Oropharyngeal Carcinoma, sponsored by Stanford University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05880797 is a study of Human Papilloma Virus and Oropharyngeal Carcinoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 1,000 participants, above the 586-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05880797, a study of Human Papilloma Virus and Oropharyngeal Carcinoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the natural history of oropharyngeal carcinoma (OPC), with or without an association with the human papilloma virus (HPV). For this study, the investigators plan to collect blood from OPC patients prior to treatment and at six subsequent time points.
Conditions Studied
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2026-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05880797
The ClinicalTrials.gov registry entry for NCT05880797 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 586-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (71% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 0 interventions.
NCT05880797 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05880797 about?
NCT05880797 is a clinical study titled "Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma". The purpose of this study is to better understand the natural history of oropharyngeal carcinoma (OPC), with or without an association with the human papilloma virus (HPV). For this study, the investigators plan to collect blood from OPC patients prior to treatment and at six subsequent time points.
What is the current status of trial NCT05880797?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-07-07. Estimated completion is 2026-08.
What conditions does trial NCT05880797 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Oropharyngeal Carcinoma.
Who is sponsoring clinical trial NCT05880797?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05880797 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.